

STAIR VI
STROKE TREATMENT
ACADEMIC INDUSTRY ROUNDTABLE

***“Acute Stroke Treatment:
A Time for Innovation”***

*Arlington, VA
March 8th & 9th 2008*

STAIR VI Program

Saturday, March 8th Morning

7:00—8:00 FULL BREAKFAST PROVIDED
Salon A & B First Floor

All Sessions for the day are in Salons J & K

8:00—8:15 WELCOME — OVERVIEW OF CONFERENCE GOALS & IMPACT OF PRIOR STAIRS

- Welcoming Remarks – Conference Chair – *Marc Fisher*
- Introduction – *Vladimir Hachinski*

8:15—10:15 SESSION 1: UPDATING THE STAIR PRECLINICAL RECOMMENDATIONS

Session Co-chairs – D. Hess & T. Jacobs

- An Assessment of the STAIR I Preclinical Recommendations and Suggested Modifications – *R. Traystman*
- Quality Control in Preclinical Studies – *M. MacLeod*
- Preclinical Testing of Devices – *M. Gounis*
- Industry Considerations for Preclinical Drug/Device Development – *G. Feuerstein*
- ROUNDTABLE PANEL DISCUSSION: “PRECLINICAL RECS. PAST AND PRESENT”
R. Traystman, M. McLeod, M. Gounis, G. Feuerstein, T. Kent, S. Finklestein, J. Aronowski

10:15—10:30 Refreshment Break *Foyer Outside Salon J & K*

10:30—11:00 ACUTE STROKE TREATMENT: A TIME FOR INNOVATIVE THINKING – *Joseph Broderick*
Brief Discussion Moderated by *P. Gorelick*

11:00—12:45 SESSION 2: IS THERE A FUTURE FOR NEUROPROTECTION?

Session Co-chairs – A. Bach & W. Koroshetz

- Lessons from the NXY-059 Preclinical Development Program – *D. Howells*
- Can Neuroprotection Succeed As A Stand Alone Therapy? – *K. Lees*
- Pharmacological and Methodological Approaches to Future Neuroprotection Studies – *S. Savitz*
- Are Modest Benefits Likely To Be Observed With Neuroprotection Clinically Meaningful and Economically Viable? – *W. Wasiewski*
- ROUNDTABLE PANEL DISCUSSION: “NEUROPROTECTION’S FUTURE”
D. Howells, K. Lees, S. Savitz, W. Wasiewski, V. Skvortsova, A. Schneider, D. Hanley, J. Broderick

12:45—1:45 LUNCHEON PROVIDED – Sponsored by Legend Merchant Group
Salon 1 & 2

*Guest Speaker
Tom Gallagher, President*

S T A I R VI
STROKE TREATMENT
ACADEMIC INDUSTRY ROUNDTABLE

***“Acute Stroke Treatment:
A Time for Innovation”***

Saturday, March 8th Afternoon
Salon J & K

**1:45—3:45 SESSION 3: STRATEGIES FOR EXTENDING THE THERAPEUTIC TIME WINDOW
FOR DRUGS AND DEVICES**

Session Co-chairs – H. Altman & R Sacco

- **Is Penumbral Imaging Necessary for Extending the Therapeutic Time Window? – Pro Vs. Con**
Pro: C. Kidwell Con: P. Lyden
- **Penumbral Imaging: MRI, CT or Both? – M. Wintermark**
- **Current Phase II/III Trials With or Without Penumbral Imaging– W. Schabitz**
- **Regulatory Perspectives on Penumbral Imaging-Based Stroke Trials – B. Dunn, FDA**
- **ROUNDTABLE PANEL DISCUSSION: “EXTENDING THE THERAPEUTIC WINDOW”**
C. Kidwell, P. Lyden, M. Wintermark, W. Schabitz, B. Dunn, W. Söehngen, S. Warach, D. Levy

3:45—4:00 Refreshment Break Foyer Outside Salon J & K

4:00—6:00 SESSION 4: NOVEL DEVICE & DRUG THERAPIES TO IMPROVE STROKE OUTCOME
Session Co-chairs – L. Goldstein & A. Weiss

- **Laser Light Therapy – J. Zivin**
- **Electrical Cortical Stimulation – B. Kissela**
- **Aortic Balloon Occlusion – D. Liebeskind**
- **Drug Therapy to Enhance Recovery – S. Cramer**
- **Sphenopalatine Ganglion Stimulation – N. Bornstein**
- **ROUNDTABLE PANEL DISCUSSION: “DEVICES TO TREAT ACUTE STROKE”**
J. Zivin, N. Bornstein, D. Liebeskind, S. Cramer, B. Kissela, J. Marler, W. Smith, P. Rumm

6:30—7:30 SPONSORED RECEPTION – Sponsored By Bio-Imaging Technologies, Inc.
Salon F, G, H

7:30—9:30 DINNER -- Master of Ceremonies: Stroke Treatment Idol – Rick Atkinson
Salon C, D, E

S T A I R VI
STROKE TREATMENT
ACADEMIC INDUSTRY ROUNDTABLE

***“Acute Stroke Treatment:
A Time for Innovation”***

Day 2

Sunday, March 9th Morning

7:30—8:30 BREAKFAST PROVIDED
Salon C,D,E

All Participants: Please Convene in the Ballroom Prior to Going to Your Workshop

8:30 – 10:30 WORKSHOPS TO DEVELOP CONSENSUS RECOMMENDATIONS
Participants are divided into three groups – each to develop recommendations

Workshop 1: Recommendations for Preclinical Research:
Red Group ***Updating and Expanding the STAIR Preclinical Recommendations***
Salon F ***E. Lo, D. Howells, P. Hurn***

Workshop 2: Recommendations for Therapeutic Time Window Extension:
Blue Group ***Acute Stroke Therapy Trials Beyond 3 Hours – What Should We Test & How Should We Test IT?***
Salon G ***G. Albers, G. Howard, J. Saver***

Workshop 3: Recommendations for Regulatory & Organizational Aspects:
Green Group ***Acute Stroke Therapy Trials Beyond 3 Hours: Regulatory and Organizational Aspects***
Salon J & K ***T. Furlan, K. Johnston, M. Walton***

10:30 – 11:00 Refreshment Break *Foyer Outside Salon J & K*

11:00—12:15 WORKSHOP CHAIRS PRESENT RECOMMENDATIONS from their group with
Salon J & K **general discussion. Drafting of consensus statement is initiated.**
Chaired by M. Fisher

12:15—12:30 CLOSING COMMENTS AND ADJOURNMENT

————— ***Thank You for Your Participation*** —————